华兰疫苗
(301207)
| 流通市值：24.62亿 | | | 总市值：104.46亿 |
| 流通股本：1.42亿 | | | 总股本：6.01亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 623,035,019.91 | 531,251,202.49 | 1,262,493,425.6 | 623,990,420.48 |
| 应收票据及应收账款 | 1,437,459,795.12 | 1,707,541,207.7 | 1,173,374,366.22 | 1,576,861,211.76 |
| 应收账款 | 1,437,459,795.12 | 1,707,541,207.7 | 1,173,374,366.22 | 1,576,861,211.76 |
| 应收款项融资 | 93,200 | 454,290 | 2,056,100 | - |
| 预付款项 | 56,926,651.42 | 51,176,276.66 | 48,198,967.46 | 43,895,757.12 |
| 其他应收款合计 | 407,626.91 | 596,118.75 | 735,402.84 | 2,561,251.77 |
| 存货 | 208,838,834.75 | 243,832,814.78 | 378,069,405.87 | 321,521,477.26 |
| 一年内到期的非流动资产 | 1,145,411,319.45 | 659,849,472.23 | 303,004,000 | 346,805,555.56 |
| 其他流动资产 | 46,202,016.07 | 89,451,728.06 | 9,627,516.06 | - |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 4,976,519,526.9 | 4,631,880,229.62 | 4,443,507,039.34 | 5,313,164,810.94 |
| 非流动资产: | | | | |
| 固定资产 | 1,062,914,404.05 | 1,085,270,076.35 | 1,108,987,929.81 | 1,144,765,707.5 |
| 在建工程 | 6,717,841.22 | 5,329,779.2 | 4,092,452 | 4,092,452 |
| 生产性生物资产 | 929,509.83 | 856,329.92 | - | 367,153.15 |
| 无形资产 | 20,882,095.23 | 19,636,667.91 | 19,799,853.53 | 19,963,039.13 |
| 开发支出 | 27,791,873.06 | 27,635,945.37 | 27,442,684.48 | 26,915,859.53 |
| 长期待摊费用 | 0 | 417,314.48 | 834,628.95 | 1,251,943.44 |
| 递延所得税资产 | 212,727,411.11 | 180,517,240.5 | 216,469,337.79 | 212,590,324.26 |
| 其他非流动资产 | 1,214,773,182.18 | 1,690,105,199.35 | 1,437,992,529.07 | 1,086,065,175.63 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,546,736,316.68 | 3,009,768,553.08 | 2,815,619,415.63 | 2,496,011,654.64 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 7,523,255,843.58 | 7,641,648,782.7 | 7,259,126,454.97 | 7,809,176,465.58 |
| 流动负债: | | | | |
| 短期借款 | 300,183,333.33 | 300,000,000 | 300,000,000 | 300,000,000 |
| 应付票据及应付账款 | 81,775,955.35 | 79,728,554.39 | 106,423,176.05 | 142,908,189.43 |
| 其中：应付票据 | - | 6,907,330 | 12,014,340 | 19,863,430 |
| 应付账款 | 81,775,955.35 | 72,821,224.39 | 94,408,836.05 | 123,044,759.43 |
| 合同负债 | 8,737,196.12 | 6,920,561.17 | 14,525,756.93 | 6,866,784.94 |
| 应付职工薪酬 | 0 | - | - | 45,385.55 |
| 应交税费 | 2,300,826.32 | 7,794,516.19 | 2,069,071.1 | 2,290,880.72 |
| 其他应付款合计 | 998,362,653.95 | 1,108,665,784.01 | 877,225,209.91 | 1,004,722,672.07 |
| 应付股利 | 29,160,000 | 28,552,500 | 28,552,500 | - |
| 其他流动负债 | 72,762,800.03 | 207,560.8 | 435,716.62 | 205,916.01 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,464,122,765.1 | 1,503,316,976.56 | 1,300,678,930.61 | 1,457,039,828.72 |
| 非流动负债: | | | | |
| 递延收益 | 27,187,976.86 | 28,246,520.52 | 29,305,064.18 | 30,363,607.84 |
| 递延所得税负债 | 18,800,579.72 | 15,904,097.27 | 13,605,153.04 | 14,561,322.29 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 45,988,556.58 | 44,150,617.79 | 42,910,217.22 | 44,924,930.13 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,510,111,321.68 | 1,547,467,594.35 | 1,343,589,147.83 | 1,501,964,758.85 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 601,027,500 | 601,027,500 | 601,027,500 | 600,015,000 |
| 资本公积 | 2,926,104,947.03 | 2,944,689,701.37 | 2,940,091,455.95 | 2,920,707,131.72 |
| 减:库存股 | 106,786,852.51 | 106,786,852.51 | 38,747,197.5 | - |
| 盈余公积 | 300,513,750 | 286,156,631.76 | 286,156,631.76 | 286,156,631.76 |
| 未分配利润 | 2,292,285,177.38 | 2,369,094,207.73 | 2,127,008,916.93 | 2,500,332,943.25 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 6,013,144,521.9 | 6,094,181,188.35 | 5,915,537,307.14 | 6,307,211,706.73 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 6,013,144,521.9 | 6,094,181,188.35 | 5,915,537,307.14 | 6,307,211,706.73 |
| 负债和股东权益合计 | 7,523,255,843.58 | 7,641,648,782.7 | 7,259,126,454.97 | 7,809,176,465.58 |
| 公告日期 | 2025-03-29 | 2024-10-30 | 2024-08-30 | 2024-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |